Ριβαροξαμπάνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ριβαροξαμπάνη" in Greek language version.

refsWebsite

Global rank Greek rank

19nih.gov

4^th place

11doi.org

2^nd place

3^rd place

3drugs.com

399^th place

130^th place

3fda.gov

447^th place

368^th place

2clincalc.com

3,912^th place

594^th place

2europa.eu

68^th place

24^th place

1xarelto.com

low place

1books.google.com

3^rd place

6^th place

1bloomberg.com

99^th place

261^st place

1annals.org

low place

2,967^th place

1nice.org.uk

3,258^th place

2,509^th place

1web.archive.org

1^st place

1webmd.com

1,169^th place

603^rd place

1rxlist.com

7,927^th place

3,123^rd place

1uzh.ch

3,633^rd place

3,413^th place

1drugnews.net

low place

1globenewswire.com

2,614^th place

low place

1reuters.com

49^th place

98^th place

annals.org

«Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review». Annals of Internal Medicine 169 (11): 774–787. December 2018. doi:10.7326/M18-1523. PMID 30383133. PMC 6825839. http://annals.org/article.aspx?doi=10.7326/M18-1523.

bloomberg.com

«Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug». 2019-04-22. https://www.bloomberg.com/news/articles/2018-07-13/bayer-j-j-win-ruling-that-upholds-patent-for-xarelto-drug. Ανακτήθηκε στις 2019-04-24.

books.google.com

Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. σελ. 11. ISBN 9783319546438.

clincalc.com

«The Top 300 of 2021». ClinCalc. Ανακτήθηκε στις 18 Φεβρουαρίου 2021.
«Rivaroxaban - Drug Usage Statistics». ClinCalc. Ανακτήθηκε στις 18 Φεβρουαρίου 2021.

doi.org

dx.doi.org

«Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review». Annals of Internal Medicine 169 (11): 774–787. December 2018. doi:10.7326/M18-1523. PMID 30383133. PMC 6825839. http://annals.org/article.aspx?doi=10.7326/M18-1523.
«Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups». Thrombosis 2013: 640723. 2013. doi:10.1155/2013/640723. PMID 24455237.
«A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons». Journal of the American Academy of Dermatology 72 (3): 524–34. March 2015. doi:10.1016/j.jaad.2014.10.027. PMID 25486915.
«Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review». Health Services Insights 9 (Suppl 1): 25–36. 2016. doi:10.4137/HSI.S40701. PMID 28008269.
«Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects». British Journal of Clinical Pharmacology 76 (3): 455–66. September 2013. doi:10.1111/bcp.12075. PMID 23305158.
«Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system». British Journal of Clinical Pharmacology 80 (2): 285–93. August 2015. doi:10.1111/bcp.12611. PMID 25689417.
«Rivaroxaban postmarketing risk of liver injury». Journal of Hepatology 61 (2): 293–300. August 2014. doi:10.1016/j.jhep.2014.03.026. PMID 24681117. http://www.zora.uzh.ch/id/eprint/94814/1/2014_J_Hepatol_rivaroxaban_russmann.pdf.
«Recent advances in the development of specific antidotes for target-specific oral anticoagulants». Pharmacotherapy 35 (2): 198–207. February 2015. doi:10.1002/phar.1532. PMID 25644580.
«Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor». Journal of Medicinal Chemistry 48 (19): 5900–8. September 2005. doi:10.1021/jm050101d. PMID 16161994.
«New oral anticoagulants in atrial fibrillation». European Heart Journal 29 (2): 155–65. January 2008. doi:10.1093/eurheartj/ehm575. PMID 18096568.
«A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement». Circulation 114 (22): 2374–81. November 2006. doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766.

drugnews.net

«Possible Antidote Could Help Blood Thinner Patients In Bleeding Emergencies». DrugNews. Ανακτήθηκε στις 20 Αυγούστου 2015.

drugs.com

«Rivaroxaban Use During Pregnancy». Drugs.com. Ανακτήθηκε στις 3 Μαρτίου 2019.
«Rivaroxaban Monograph for Professionals». Drugs.com. American Society of Health-System Pharmacists. Ανακτήθηκε στις 3 Μαρτίου 2019.
«Generic Xarelto Availability». Drugs.com. Ανακτήθηκε στις 9 Μαΐου 2017.

europa.eu

ema.europa.eu

«Xarelto EPAR». European Medicines Agency (EMA). Ανακτήθηκε στις 13 Νοεμβρίου 2020.

emea.europa.eu

European Medicines Agency (2008). «CHP Assessment Report for Xarelto (EMEA/543519/2008)» (PDF). Ανακτήθηκε στις 11 Ιουνίου 2009. ^{[νεκρός σύνδεσμος]}

fda.gov

«Medication Guide – Xarelto» (PDF). U.S. Food and Drug Administration. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 2 Μαΐου 2014. Ανακτήθηκε στις 1 Σεπτεμβρίου 2014.
«Accelerated Approval for AndexXa» (PDF). FDA. Ανακτήθηκε στις 1 Αυγούστου 2018.

accessdata.fda.gov

«Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations». www.accessdata.fda.gov. Ανακτήθηκε στις 24 Απριλίου 2019.

globenewswire.com

«U.S. FDA Approves Portola Pharmaceuticals' Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors». Portola Pharmaceuticals Inc. (GlobeNewswire News Room). https://globenewswire.com/news-release/2018/05/04/1496534/0/en/U-S-FDA-Approves-Portola-Pharmaceuticals-Andexxa-First-and-Only-Antidote-for-the-Reversal-of-Factor-Xa-Inhibitors.html. Ανακτήθηκε στις 1 August 2018.

nice.org.uk

«Overview | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance | NICE». www.nice.org.uk. Ανακτήθηκε στις 1 Ιανουαρίου 2020.

nih.gov

ncbi.nlm.nih.gov

«Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor». P & T 34 (5): 238–44. May 2009. PMID 19561868.
«Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review». Annals of Internal Medicine 169 (11): 774–787. December 2018. doi:10.7326/M18-1523. PMID 30383133. PMC 6825839. http://annals.org/article.aspx?doi=10.7326/M18-1523.
«Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups». Thrombosis 2013: 640723. 2013. doi:10.1155/2013/640723. PMID 24455237.
«A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons». Journal of the American Academy of Dermatology 72 (3): 524–34. March 2015. doi:10.1016/j.jaad.2014.10.027. PMID 25486915.
«Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review». Health Services Insights 9 (Suppl 1): 25–36. 2016. doi:10.4137/HSI.S40701. PMID 28008269.
«Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects». British Journal of Clinical Pharmacology 76 (3): 455–66. September 2013. doi:10.1111/bcp.12075. PMID 23305158.
«Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system». British Journal of Clinical Pharmacology 80 (2): 285–93. August 2015. doi:10.1111/bcp.12611. PMID 25689417.
«Rivaroxaban postmarketing risk of liver injury». Journal of Hepatology 61 (2): 293–300. August 2014. doi:10.1016/j.jhep.2014.03.026. PMID 24681117. http://www.zora.uzh.ch/id/eprint/94814/1/2014_J_Hepatol_rivaroxaban_russmann.pdf.
«Recent advances in the development of specific antidotes for target-specific oral anticoagulants». Pharmacotherapy 35 (2): 198–207. February 2015. doi:10.1002/phar.1532. PMID 25644580.
«Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor». Journal of Medicinal Chemistry 48 (19): 5900–8. September 2005. doi:10.1021/jm050101d. PMID 16161994.
«New oral anticoagulants in atrial fibrillation». European Heart Journal 29 (2): 155–65. January 2008. doi:10.1093/eurheartj/ehm575. PMID 18096568.
«A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement». Circulation 114 (22): 2374–81. November 2006. doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766.

pubmedcentral.nih.gov

«Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor». P & T 34 (5): 238–44. May 2009. PMID 19561868.
«Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review». Annals of Internal Medicine 169 (11): 774–787. December 2018. doi:10.7326/M18-1523. PMID 30383133. PMC 6825839. http://annals.org/article.aspx?doi=10.7326/M18-1523.
«Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups». Thrombosis 2013: 640723. 2013. doi:10.1155/2013/640723. PMID 24455237.
«Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review». Health Services Insights 9 (Suppl 1): 25–36. 2016. doi:10.4137/HSI.S40701. PMID 28008269.
«Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects». British Journal of Clinical Pharmacology 76 (3): 455–66. September 2013. doi:10.1111/bcp.12075. PMID 23305158.
«Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system». British Journal of Clinical Pharmacology 80 (2): 285–93. August 2015. doi:10.1111/bcp.12611. PMID 25689417.

dailymed.nlm.nih.gov

«Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban tablet, film coated Xarelto- rivaroxaban kit». DailyMed. Ανακτήθηκε στις 13 Νοεμβρίου 2020.

reuters.com

«New blood thinner 'antidote' to help doctors move past warfarin». Reuters. December 23, 2015. https://www.reuters.com/article/us-pharmaceuticals-bloodthinners-idUSKBN0U617320151223.

rxlist.com

«Xarelto Side Effects Center». RxList. Ανακτήθηκε στις 1 Σεπτεμβρίου 2014.

uzh.ch

zora.uzh.ch

«Rivaroxaban postmarketing risk of liver injury». Journal of Hepatology 61 (2): 293–300. August 2014. doi:10.1016/j.jhep.2014.03.026. PMID 24681117. http://www.zora.uzh.ch/id/eprint/94814/1/2014_J_Hepatol_rivaroxaban_russmann.pdf.

web.archive.org

«Medication Guide – Xarelto» (PDF). U.S. Food and Drug Administration. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 2 Μαΐου 2014. Ανακτήθηκε στις 1 Σεπτεμβρίου 2014.

webmd.com

«Xarelto Side Effects». WebMD. Ανακτήθηκε στις 1 Σεπτεμβρίου 2014.

xarelto.com

«Xarelto: Summary of Product Characteristics». Bayer Schering Pharma AG. 2008. Ανακτήθηκε στις 11 Φεβρουαρίου 2009.